Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.1 passage
• 10-year trajectory of β-cell function and insulin sensitivity in the development of type 2 diabetes: a community-based prospective cohort study.1 passage
• 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.1 passage
• 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial.1 passage
• 2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial.1 passage
• 25-hydroxyvitamin D concentrations during fetal life and bone health in children aged 6 years: a population-based prospective cohort study.1 passage
• A clinical algorithm to diagnose differences of sex development.1 passage
• A community-based, multi-level, multi-setting, multi-component intervention to reduce weight gain among low socioeconomic status Latinx children with overweight or obesity: The Stanford GOALS randomised controlled trial.1 passage
• A genetic approach to evaluation of short stature of undetermined cause.1 passage
• A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys.1 passage
• A telehealth lifestyle intervention to reduce excess gestational weight gain in pregnant women with overweight or obesity (GLOW): a randomised, parallel-group, controlled trial.1 passage
• Active commuting and obesity in mid-life: cross-sectional, observational evidence from UK Biobank.1 passage
• Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial.1 passage
• Adolescent obesity and midlife cancer risk: a population-based cohort study of 2·3 million adolescents in Israel.1 passage
• Adrenal crises in older patients.1 passage
• Adrenal myelolipomas.1 passage
• Adrenal vein sampling in primary aldosteronism: towards a standardised protocol.1 passage
• Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial.1 passage
• Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies.1 passage
• Advances in the medical treatment of Cushing's syndrome.1 passage
• Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.1 passage
• Aiding sleep in type 2 diabetes: therapeutic considerations.1 passage
• Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.1 passage
• Alcohol and illicit drug use in people with diabetes.1 passage
• An internet-based intervention with brief nurse support to manage obesity in primary care (POWeR+): a pragmatic, parallel-group, randomised controlled trial.1 passage
• Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.1 passage
• Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine.1 passage
• Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis.1 passage
• Approach to patients with hypophosphataemia.1 passage
• Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial.1 passage
• Association between borderline neonatal thyroid-stimulating hormone concentrations and educational and developmental outcomes: a population-based record-linkage study.1 passage
• Association between circulating 25-hydroxyvitamin D and incident type 2 diabetes: a mendelian randomisation study.1 passage
• Association between excessive BMI increase during puberty and risk of cardiovascular mortality in adult men: a population-based cohort study.1 passage
• Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews.1 passage
• Association between hyperglycaemia and adverse perinatal outcomes in south Asian and white British women: analysis of data from the Born in Bradford cohort.1 passage
• Association between maternal pre-pregnancy obesity and preterm birth according to maternal age and race or ethnicity: a population-based study.1 passage
• Association between type 2 diabetes and prenatal exposure to the Ukraine famine of 1932-33: a retrospective cohort study.1 passage
• Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK.1 passage
• Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study.1 passage
• Association of age and BMI with kidney function and mortality: a cohort study.1 passage
• Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study.1 passage
• Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map.1 passage
• Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study.1 passage
• Association of insulin resistance and β-cell dysfunction with incident diabetes among adults in China: a nationwide, population-based, prospective cohort study.1 passage
• Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based prospective cohort study.1 passage
• Association of maternal thyroid function with birthweight: a systematic review and individual-participant data meta-analysis.1 passage
• Association of preconception serum 25-hydroxyvitamin D concentrations with livebirth and pregnancy loss: a prospective cohort study.1 passage
• Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study.1 passage
• Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial.1 passage
• Associations between androgens and sexual function in premenopausal women: a cross-sectional study.1 passage
• Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study.1 passage
• Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study.1 passage
• Autoimmune thyroid disease during pregnancy.1 passage
• Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study.1 passage
• BMI and risk of dementia in two million people over two decades: a retrospective cohort study.1 passage
• BMI, leisure-time physical activity, and physical fitness in adults in China: results from a series of national surveys, 2000-14.1 passage
• Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery.1 passage
• Blood glucose meters and test strips: global market and challenges to access in low-resource settings.1 passage
• Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.1 passage
• Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population.1 passage
• Bone disease in diabetes: another manifestation of microvascular disease?1 passage
• Bone health during endocrine therapy for cancer.1 passage
• Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.1 passage
• COVID-19 and metabolic disease: mechanisms and clinical management.1 passage
• COVID-19 in people with diabetes: understanding the reasons for worse outcomes.1 passage
• Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.1 passage
• Cancer treatment and gonadal function: experimental and established strategies for fertility preservation in children and young adults.1 passage
• Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis.1 passage
• Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.1 passage
• Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.1 passage
• Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988-2014.1 passage
• Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study.1 passage
• Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.1 passage
• Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.1 passage
• Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.1 passage
• Cardiovascular risk factors and carotid intima media thickness in young adults born small for gestational age after cessation of growth hormone treatment: a 5-year longitudinal study.1 passage
• Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.1 passage
• Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.1 passage
• Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.1 passage
• Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.1 passage
• Catecholamine physiology and its implications in patients with COVID-19.1 passage
• Causes, consequences, and treatment of metabolically unhealthy fat distribution.1 passage
• Causes, diagnosis, and treatment of central precocious puberty.1 passage
• Central nervous pathways of insulin action in the control of metabolism and food intake.1 passage
• Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression.1 passage
• Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1.1 passage
• Challenges associated with providing diabetes care in humanitarian settings.1 passage
• Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.1 passage
• Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.1 passage
• Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study.1 passage
• Clinical aspects of thyroid function during ageing.1 passage
• Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trial.1 passage
• Clinical management and treatment of obesity in China.1 passage
• Clinical management of pregnancy in the obese mother: before conception, during pregnancy, and post partum.1 passage
• Clinical management of the uraemic syndrome in chronic kidney disease.1 passage
• Clinical management of type 2 diabetes in south Asia.1 passage
• Clinical relevance of the bile acid receptor TGR5 in metabolism.1 passage
• Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial.1 passage
• Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study.1 passage
• Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial.1 passage
• Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial.1 passage
• Community groups or mobile phone messaging to prevent and control type 2 diabetes and intermediate hyperglycaemia in Bangladesh (DMagic): a cluster-randomised controlled trial.1 passage
• Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial.1 passage
• Comparative effectiveness and cost-effectiveness of treat-to-target versus benefit-based tailored treatment of type 2 diabetes in low-income and middle-income countries: a modelling analysis.1 passage
• Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study.1 passage
• Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.1 passage
• Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.1 passage
• Complications of Cushing's syndrome: state of the art.1 passage
• Compression of disability between two birth cohorts of US adults with diabetes, 1992-2012: a prospective longitudinal analysis.1 passage
• Concepts in diagnosis and therapy for male reproductive impairment.1 passage
• Consensus on diagnosis and management of Cushing's disease: a guideline update.1 passage
• Constraints and challenges in access to insulin: a global perspective.1 passage
• Constructs of depression and distress in diabetes: time for an appraisal.1 passage
• Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial.1 passage
• Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study.1 passage
• Costs and benefits of iodine supplementation for pregnant women in a mildly to moderately iodine-deficient population: a modelling analysis.1 passage
• Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials.1 passage
• Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.1 passage
• Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.1 passage
• Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.1 passage
• Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.1 passage
• Depression and diabetes: treatment and health-care delivery.1 passage
• Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials.1 passage
• Diabetes and infection: assessing the association with glycaemic control in population-based studies.1 passage
• Diabetes diagnosis and care in sub-Saharan Africa: pooled analysis of individual data from 12 countries.1 passage
• Diabetes in ageing: pathways for developing the evidence base for clinical guidance.1 passage
• Diabetes in older people: new insights and remaining challenges.1 passage
• Diabetes in pregnancy and epigenetic mechanisms-how the first 9 months from conception might affect the child's epigenome and later risk of disease.1 passage
• Diabetes structured self-management education programmes: a narrative review and current innovations.1 passage
• Diabetes, metabolic disease, and telomere length.1 passage
• Diabetes-related metabolic risk factors in internal migrant workers in China: a national surveillance study.1 passage
• Diabetes: a metabolic and reproductive disorder in women.1 passage
• Diabetic macular oedema.1 passage
• Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention.1 passage
• Diagnosis and management of adrenal insufficiency.1 passage
• Diagnosis and treatment of primary aldosteronism.1 passage
• Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study.1 passage
• Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data.1 passage
• Distal technologies and type 1 diabetes management.1 passage
• Divergent associations of height with cardiometabolic disease and cancer: epidemiology, pathophysiology, and global implications.1 passage
• Do sulphonylureas still have a place in clinical practice?1 passage
• Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study.1 passage
• Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.1 passage
• Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.1 passage
• Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.1 passage
• Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial.1 passage
• Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.1 passage
• Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.1 passage
• Economic development and the nutritional status of Chinese school-aged children and adolescents from 1995 to 2014: an analysis of five successive national surveys.1 passage
• Effect of a behavioural intervention in obese pregnant women (the UPBEAT study): a multicentre, randomised controlled trial.1 passage
• Effect of a high-fat Mediterranean diet on bodyweight and waist circumference: a prespecified secondary outcomes analysis of the PREDIMED randomised controlled trial.1 passage
• Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.1 passage
• Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.1 passage
• Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials.1 passage
• Effect of cancer treatment on hypothalamic-pituitary function.1 passage
• Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.1 passage
• Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.1 passage
• Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.1 passage
• Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study.1 passage
• Effect of diabetes on tuberculosis control in 13 countries with high tuberculosis: a modelling study.1 passage
• Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study.1 passage
• Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial.1 passage
• Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial.1 passage
• Effect of iodine supplementation in pregnant women on child neurodevelopment: a randomised, double-blind, placebo-controlled trial.1 passage
• Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis.1 passage
• Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial.1 passage
• Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.1 passage
• Effect of metformin pretreatment on myocardial injury during coronary artery bypass surgery in patients without diabetes (MetCAB): a double-blind, randomised controlled trial.1 passage
• Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary and post-hoc outcomes from the randomised, double-blind, placebo-controlled ViDA trial.1 passage
• Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.1 passage
• Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial.1 passage
• Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.1 passage
• Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials.1 passage
• Effect of vitamin D supplementation on non-skeletal disorders: a systematic review of meta-analyses and randomised trials.1 passage
• Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.1 passage
• Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial.1 passage
• Effectiveness of activity trackers with and without incentives to increase physical activity (TRIPPA): a randomised controlled trial.1 passage
• Effectiveness of an mHealth intervention to improve the cardiometabolic profile of people with prehypertension in low-resource urban settings in Latin America: a randomised controlled trial.1 passage
• Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis.1 passage
• Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.1 passage
• Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.1 passage
• Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.1 passage
• Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.1 passage
• Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.1 passage
• Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants.1 passage
• Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.1 passage
• Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.1 passage
• Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.1 passage
• Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.1 passage
• Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.1 passage
• Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial.1 passage
• Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.1 passage
• Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.1 passage
• Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.1 passage
• Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis.1 passage
• Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.1 passage
• Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.1 passage
• Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.1 passage
• Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial.1 passage
• Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.1 passage
• Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.1 passage
• Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.1 passage
• Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.1 passage
• Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.1 passage
• Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.1 passage
• Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.1 passage
• Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.1 passage
• Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.1 passage
• Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.1 passage
• Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.1 passage
• Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.1 passage
• Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.1 passage
• Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.1 passage
• Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.1 passage
• Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.1 passage
• Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.1 passage
• Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.1 passage
• Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial.1 passage
• Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: a systematic review and meta-analysis.1 passage
• Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.1 passage
• Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.1 passage
• Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction.1 passage
• Endocrine-disrupting chemicals: economic, regulatory, and policy implications.1 passage
• Endocrine-disrupting chemicals: implications for human health.1 passage
• Epidemiology and determinants of obesity in China.1 passage
• Epidemiology and determinants of type 2 diabetes in south Asia.1 passage
• Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study.1 passage
• Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: a nested case-control study.1 passage
• Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.1 passage
• Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data.1 passage
• Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses.1 passage
• Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimulation analysis.1 passage
• Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study.1 passage
• Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.1 passage
• Exercise management in type 1 diabetes: a consensus statement.1 passage
• Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis.1 passage
• Exposure to endocrine-disrupting chemicals in the USA: a population-based disease burden and cost analysis.1 passage
• Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT Untethered): a single-centre, open-label, proof-of-concept, randomised crossover trial.1 passage
• Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management.1 passage
• Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study.1 passage
• Frailty and the endocrine system.1 passage
• Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank.1 passage
• Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial.1 passage
• Functional neuroimaging in obesity and the potential for development of novel treatments.1 passage
• Future glucose-lowering drugs for type 2 diabetes.1 passage
• Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial.1 passage
• Gender-affirming hormones and surgery in transgender children and adolescents.1 passage
• Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population.1 passage
• Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications.1 passage
• Gestational diabetes: opportunities for improving maternal and child health.1 passage
• Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study.1 passage
• Glucose management in critically ill adults and children.1 passage
• Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review.1 passage
• Glucose screening in pregnancy and future risk of cardiovascular disease in women: a retrospective, population-based cohort study.1 passage
• Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials.1 passage
• Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.1 passage
• Glycaemic management in diabetes: old and new approaches.1 passage
• Glycaemic status during pregnancy and longitudinal measures of fetal growth in a multi-racial US population: a prospective cohort study.1 passage
• Glycaemic variability in diabetes: clinical and therapeutic implications.1 passage
• Gradual reduction of sugar in soft drinks without substitution as a strategy to reduce overweight, obesity, and type 2 diabetes: a modelling study.1 passage
• Growth monitoring as an early detection tool: a systematic review.1 passage
• Guideline recommendations and the positioning of newer drugs in type 2 diabetes care.1 passage
• Health policy and public health implications of obesity in China.1 passage
• Health-care costs over 15 years after bariatric surgery for patients with different baseline glucose status: results from the Swedish Obese Subjects study.1 passage
• High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study.1 passage
• Hyperinsulinaemic hypoglycaemia in children and adults.1 passage
• Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management.1 passage
• Identifying adults at high-risk for change in weight and BMI in England: a longitudinal, large-scale, population-based cohort study using electronic health records.1 passage
• Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.1 passage
• Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.1 passage
• Inadequate β-cell mass is essential for the pathogenesis of type 2 diabetes.1 passage
• Incidence and progression of diabetic retinopathy: a systematic review.1 passage
• Infection and antibiotic use in infancy and risk of childhood obesity: a longitudinal birth cohort study.1 passage
• Influence of maternal obesity on the long-term health of offspring.1 passage
• Intake and metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional implications for cardiometabolic diseases.1 passage
• Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes.1 passage
• Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants.1 passage
• Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials.1 passage
• Intermediate hyperglycaemia to predict progression to type 2 diabetes (ELSA-Brasil): an occupational cohort study in Brazil.1 passage
• Interventions to prevent global childhood overweight and obesity: a systematic review.1 passage
• Interventions to prevent maternal obesity before conception, during pregnancy, and post partum.1 passage
• Iodine deficiency and thyroid disorders.1 passage
• Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial.1 passage
• Key European guidelines for the diagnosis and management of patients with phenylketonuria.1 passage
• Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.1 passage
• Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys.1 passage
• Laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity (AMOS): a prospective, 5-year, Swedish nationwide study.1 passage
• LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial.1 passage
• Leveraging the immune system to treat advanced thyroid cancers.1 passage
• Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study.1 passage
• Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data.1 passage
• Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.1 passage
• Long working hours, socioeconomic status, and the risk of incident type 2 diabetes: a meta-analysis of published and unpublished data from 222 120 individuals.1 passage
• Long-term adverse events after sleeve gastrectomy or gastric bypass: a 7-year nationwide, observational, population-based, cohort study.1 passage
• Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial.1 passage
• Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.1 passage
• Long-term effects of neighbourhood deprivation on diabetes risk: quasi-experimental evidence from a refugee dispersal policy in Sweden.1 passage
• Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study.1 passage
• Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study.1 passage
• Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study.1 passage
• Long-term outcomes of bariatric surgery in adolescents with severe obesity (FABS-5+): a prospective follow-up analysis.1 passage
• Long-term outcomes of kidney transplantation in people with type 2 diabetes: a population cohort study.1 passage
• Long-term population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: a retrospective, nationwide, cohort study.1 passage
• Long-term risk of anaemia after bariatric surgery: results from the Swedish Obese Subjects study.1 passage
• Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study.1 passage
• Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.1 passage
• Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study.1 passage
• Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?1 passage
• Male hormonal contraception: hope and promise.1 passage
• Management of advanced medullary thyroid cancer.1 passage
• Management of diabetes and hyperglycaemia in the hospital.1 passage
• Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature.1 passage
• Maternal gestational vitamin D supplementation and offspring bone health (MAVIDOS): a multicentre, double-blind, randomised placebo-controlled trial.1 passage
• Maternal health, in-utero, and perinatal exposures and risk of thyroid cancer in offspring: a Nordic population-based nested case-control study.1 passage
• Maternal obesity and risk of cardiovascular diseases in offspring: a population-based cohort and sibling-controlled study.1 passage
• Maternal thyroid function during pregnancy and child brain morphology: a time window-specific analysis of a prospective cohort.1 passage
• Mean HbA1 passage
• Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data.1 passage
• Metabolic health in the Middle East and north Africa.1 passage
• Metabolic health of young adults who were born small for gestational age and treated with growth hormone, after cessation of growth hormone treatment: a 5-year longitudinal study.1 passage
• Metabolic syndrome: a sympathetic disease?1 passage
• Metabolically healthy obesity: the low-hanging fruit in obesity treatment?1 passage
• Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial.1 passage
• Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.1 passage
• Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study.1 passage
• Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study.1 passage
• Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.1 passage
• Monogenic autoimmune diseases of the endocrine system.1 passage
• Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study.1 passage
• Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study.1 passage
• Mortality risk among sulfonylureas: a systematic review and network meta-analysis.1 passage
• Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria.1 passage
• Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.1 passage
• Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.1 passage
• Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis.1 passage
• Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study.1 passage
• New forms of insulin and insulin therapies for the treatment of type 2 diabetes.1 passage
• New insights into the controversy of adrenal function during critical illness.1 passage
• New ophthalmologic imaging techniques for detection and monitoring of neurodegenerative changes in diabetes: a systematic review.1 passage
• New pharmacological strategies for protecting kidney function in type 2 diabetes.1 passage
• Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.1 passage
• Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.1 passage
• Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes.1 passage
• Novel concepts in the aetiology of male reproductive impairment.1 passage
• Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables.1 passage
• Nutritional intake and bone health.1 passage
• Nutritional support in critical illness and recovery.1 passage
• Obesity in people living with type 1 diabetes.1 passage
• Obesity, inflammation, and the gut microbiota.1 passage
• Objective assessment of dietary patterns by use of metabolic phenotyping: a randomised, controlled, crossover trial.1 passage
• Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.1 passage
• Oestrogen and anti-androgen therapy for transgender women.1 passage
• Oestrogen versus androgen in hormone-replacement therapy for complete androgen insensitivity syndrome: a multicentre, randomised, double-dummy, double-blind crossover trial.1 passage
• Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies.1 passage
• Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study.1 passage
• Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals.1 passage
• Opioid-induced endocrinopathies.1 passage
• Optimisation of follow-up after metabolic surgery.1 passage
• Osteoporosis treatment: recent developments and ongoing challenges.1 passage
• Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial.1 passage
• Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort.1 passage
• Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial.1 passage
• PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.1 passage
• Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance?1 passage
• Pathophysiology and management of cardiovascular disease in patients with HIV.1 passage
• Phenotypes of prediabetes and stratification of cardiometabolic risk.1 passage
• Physical activity and skeletal health in adults.1 passage
• Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis.1 passage
• Pleiotropic effects of type 2 diabetes management strategies on renal risk factors.1 passage
• Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial.1 passage
• Post-exercise recovery for the endurance athlete with type 1 diabetes: a consensus statement.1 passage
• Post-transplantation diabetes-state of the art.1 passage
• Practical definitions of severe versus familial hypercholesterolaemia and hypertriglyceridaemia for adult clinical practice.1 passage
• Practical recommendations for the management of diabetes in patients with COVID-19.1 passage
• Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.1 passage
• Precision medicine in the management of type 2 diabetes.1 passage
• Precision nutrition for prevention and management of type 2 diabetes.1 passage
• Preconceptional and maternal obesity: epidemiology and health consequences.1 passage
• Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.1 passage
• Prevalence of behavioural risk factors for cardiovascular disease in adolescents in low-income and middle-income countries: an individual participant data meta-analysis.1 passage
• Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study.1 passage
• Prevalence of obesity, hypertension, and diabetes, and cascade of care in sub-Saharan Africa: a cross-sectional, population-based study in rural and urban Malawi.1 passage
• Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study.1 passage
• Progress and challenges in anti-obesity pharmacotherapy.1 passage
• Pubertal development and regulation.1 passage
• Puberty suppression in transgender children and adolescents.1 passage
• Public health and health systems: implications for the prevention and management of type 2 diabetes in south Asia.1 passage
• Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.1 passage
• Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement.1 passage
• Recent advances in the pharmacological management of hypercholesterolaemia.1 passage
• Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.1 passage
• Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism.1 passage
• Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?1 passage
• Reference intervals in the diagnosis of thyroid dysfunction: treating patients not numbers.1 passage
• Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis.1 passage
• Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.1 passage
• Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.1 passage
• Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.1 passage
• Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial.1 passage
• Reporting standards of studies and papers on the prevention and management of foot ulcers in diabetes: required details and markers of good quality.1 passage
• Rethinking good cholesterol: a clinicians' guide to understanding HDL.1 passage
• Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes.1 passage
• Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study.1 passage
• Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study.1 passage
• Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.1 passage
• Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study.1 passage
• Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study.1 passage
• Risk of suicide and non-fatal self-harm after bariatric surgery: results from two matched cohort studies.1 passage
• Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland.1 passage
• Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial.1 passage
• SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.1 passage
• SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.1 passage
• Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.1 passage
• Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data.1 passage
• Screening and management of adverse endocrine outcomes in adult survivors of childhood and adolescent cancer.1 passage
• Screening for diabetic retinopathy: new perspectives and challenges.1 passage
• Screening for differentiated thyroid cancer in selected populations.1 passage
• Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.1 passage
• Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.1 passage
• Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies.1 passage
• Shared decision making in endocrinology: present and future directions.1 passage
• Skeletal health in adults with HIV infection.1 passage
• Smoking cessation and weight change in relation to cardiovascular disease incidence and mortality in people with type 2 diabetes: a population-based cohort study.1 passage
• Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.1 passage
• Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES).1 passage
• Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial.1 passage
• Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study.1 passage
• Sweetening of the global diet, particularly beverages: patterns, trends, and policy responses.1 passage
• Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial.1 passage
• Targeting weight loss interventions to reduce cardiovascular complications of type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous treatment effects in the Look AHEAD trial.1 passage
• Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study.1 passage
• Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.1 passage
• Testosterone in women--the clinical significance.1 passage
• Testosterone therapy for transgender men.1 passage
• Testosterone treatment in older men: clinical implications and unresolved questions from the Testosterone Trials.1 passage
• Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial.1 passage
• The association between smoking cessation and glycaemic control in patients with type 2 diabetes: a THIN database cohort study.1 passage
• The bone-fat interface: basic and clinical implications of marrow adiposity.1 passage
• The burden of diabetes and use of diabetes care in humanitarian crises in low-income and middle-income countries.1 passage
• The challenge of modulating β-cell autoimmunity in type 1 diabetes.1 passage
• The changing face of diabetes complications.1 passage
• The dietary transition and its association with cardiometabolic mortality among Chinese adults, 1982-2012: a cross-sectional population-based study.1 passage
• The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.1 passage
• The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.1 passage
• The effect of vitamin D supplementation on acute respiratory tract infection in older Australian adults: an analysis of data from the D-Health Trial.1 passage
• The global diabetes epidemic: what does it mean for infectious diseases in tropical countries?1 passage
• The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study.1 passage
• The importance of language in engagement between health-care professionals and people living with obesity: a joint consensus statement.1 passage
• The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions.1 passage
• The link between depression and diabetes: the search for shared mechanisms.1 passage
• The metabolic burden of sleep loss.1 passage
• The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data.1 passage
• The obesity transition: stages of the global epidemic.1 passage
• The physiology of endocrine systems with ageing.1 passage
• The prevalence of type 2 diabetes among older people in Africa: a systematic review.1 passage
• The role of blood volume in cardiac dysfunction and reduced exercise tolerance in patients with diabetes.1 passage
• The sex-specific association between BMI and coronary heart disease: a systematic review and meta-analysis of 95 cohorts with 1·2 million participants.1 passage
• Thyroid cancer incidence trends by histology in 25 countries: a population-based study.1 passage
• Thyroid function in critically ill patients.1 passage
• Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86).1 passage
• Towards unified and impactful policies to reduce ultra-processed food consumption and promote healthier eating.1 passage
• Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses' Health Study): 30 year follow-up from a prospective cohort study.1 passage
• Treatment of hypopituitarism in patients receiving antiepileptic drugs.1 passage
• Treatment of type 2 diabetes: challenges, hopes, and anticipated successes.1 passage
• Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials.1 passage
• Trends in hospital admissions for hypoglycaemia in England: a retrospective, observational study.1 passage
• Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records.1 passage
• Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records.1 passage
• Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings.1 passage
• Type 1 diabetes-early life origins and changing epidemiology.1 passage
• Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities.1 passage
• Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people.1 passage
• Type 2 diabetes and the skeleton: new insights into sweet bones.1 passage
• Type 2 diabetes in adolescents and young adults.1 passage
• Type 2 diabetes in migrant south Asians: mechanisms, mitigation, and management.1 passage
• US initiative for prediabetes.1 passage
• Understanding the mechanisms of reversal of type 2 diabetes.1 passage
• Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study.1 passage
• Use of bone turnover markers in postmenopausal osteoporosis.1 passage
• Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.1 passage
• Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial.1 passage
• Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial.1 passage
• Using social and mobile tools for weight loss in overweight and obese young adults (Project SMART): a 2 year, parallel-group, randomised, controlled trial.1 passage
• Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement.1 passage
• Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials.1 passage
• Web-based cognitive behavioural therapy blended with face-to-face sessions for chronic fatigue in type 1 diabetes: a multicentre randomised controlled trial.1 passage
• Weight loss and incidence of diabetes with the Veterans Health Administration MOVE! lifestyle change programme: an observational study.1 passage
• Work stress and risk of death in men and women with and without cardiometabolic disease: a multicohort study.1 passage
• Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment.2 passages
• Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study.1 passage